Better Health for All

Evoke Pharma's sole product, GIMOTI, delivers transformative health benefits for patients with diabetic gastroparesis, reducing emergency room visits by 60% and hospitalizations by 68%, and lowering the total cost of care by $15,000 within six months.

As the company's entire business is devoted to this product, which is a treatment for a specific GI disorder, it has no revenue from products with negative health outcomes. However, GIMOTI carries significant safety risks, including a boxed warning for tardive dyskinesia (TD), which can be irreversible, and other serious adverse events like neuroleptic malignant syndrome and depression. While these risks are transparently disclosed in product labeling and press releases, the potential for severe, irreversible harm is notable. The company offers financial assistance programs, including a $0 or $20 copay for eligible patients, and has expanded access to Medicaid patients in several states, with Medicare and Medicaid accounting for approximately 34% of filled prescriptions in the first nine months of 2024. The company's R&D expenses were $16,322 in 2024, a significant decrease from $181,907 in 2023. Evoke Pharma secured two new U.S. patent allowances in December 2024, which were issued and Orange-book listed in Q1 2025.

Fair Money & Economic Opportunity

Evoke Pharma, Inc. is a specialty pharmaceutical company focused on developing and commercializing treatments for gastrointestinal disorders, specifically the drug GIMOTI.

The company's core business is the sale of a medical product, not financial services. The 'Fair Money & Economic Opportunity' value and its associated KPIs are designed to assess financial institutions on aspects such as lending, fees, debt, and financial literacy for consumers. As Evoke Pharma does not offer lending or deposit services, nor does it engage in financial activities for consumers, all KPIs are deemed 'Not applicable' (score 0) due to a lack of relevant evidence within the scope of financial services.

Fair Pay & Worker Respect

The CEO to median employee pay ratio for 2023 was approximately 18.43:1, based on CEO David Gonyer's compensation of $1,207,059 and the average U.S. worker wage of $65,470.

Employee engagement, as indicated by a Glassdoor employee rating, is 3.7 out of 5 stars (equivalent to 74/100). While 50% of employees would recommend working at Evoke, reviews also highlight concerns about management, frequent layoffs, and a perceived lack of employee engagement and support.

Honest & Fair Business

Evoke Pharma has a whistleblower policy that encourages reporting to a supervisor or Chief Business Officer with confidentiality promises.

An ethics helpline monitored by the Audit Committee for anonymous reports. The company reported one financial restatement in its December 31, 2024 filing to correct an error in previously issued financial statements. The Audit Committee, Compensation Committee, and Nominating & Corporate Governance Committee are composed entirely of independent directors. A majority of the board must be independent under Nasdaq standards. The company has adopted a Code of Business Conduct and Ethics that prohibits bribery and kickbacks, with specific guidelines for interactions with government officials.

Kind to Animals

The company's pre-clinical tests include animal studies to assess product characteristics, safety, and efficacy.

These studies are conducted in compliance with FDA’s good laboratory practice regulations. There is no evidence of a policy to prohibit discretionary testing or to actively reduce or replace animal testing beyond regulatory mandates.

Respect for Cultures & Communities

No specific data or information regarding EVOK.US's performance on 'Respect for Cultures & Communities' was found in the provided articles.

All articles explicitly state that they contain no quantitative data, regulatory actions, certifications, or other details relevant to any of the specified key metrics for the company.